Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wolfe Research Initiates Coverage On Procore Technologies with Peer Perform Rating

Wolfe Research Initiates Coverage On Procore Technologies with Peer Perform Rating

Wolfe Research analyst Gal Munda initiates coverage on Procore Technologies (NYSE:PCOR) with a Peer Perform rating.

byBenzinga Newsdesk

August 17, 2022

1 minute read

Wolfe Research analyst Gal Munda initiates coverage on Procore Technologies (NYSE:PCOR) with a Peer Perform rating.

Citigroup Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $235

By Benzinga Newsdesk

July 22, 10:54 AM

Citigroup analyst Fatima Boolani maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Buy and lowers the price target from $245 to $235.

CRWD

Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases

By Vandana Singh

January 10, 1:22 PM

Jasper Therapeutics Inc (NASDAQ:JSPR) will focus on developing its lead product candidate, briquilimab (formerly JSP191), in chronic diseases and stem…

JSPR

Analyst Ratings

Analyst Ratings for Corcept Therapeutics

By Benzinga Insights

April 4, 8:01 AM

Corcept Therapeutics (NASDAQ:CORT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CORT

Oppenheimer Reiterates Outperform on Five Below, Maintains $235 Price Target

By Benzinga Newsdesk

March 17, 8:06 AM

Oppenheimer analyst Brian Nagel reiterates Five Below (NASDAQ:FIVE) with a Outperform and maintains $235 price target.

FIVE

Wolfe Research Initiates Coverage On Procore Technologies with Peer Perform Rating

Related Posts

Citigroup Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $235

Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases

Analyst Ratings for Corcept Therapeutics

Oppenheimer Reiterates Outperform on Five Below, Maintains $235 Price Target